Browsing Tag
Inhibikase Therapeutics
3 posts
IKT-001 gains orphan status, but Inhibikase Therapeutics still faces imatinib’s safety challenge
Inhibikase Therapeutics gains FDA orphan status for IKT-001 after a $50 million raise. See how trial costs and dilution shape the outlook.
Why Wall Street and clinicians may be watching IKT-001 more closely after the Phase 3 launch
Could IKT-001 change the PAH treatment landscape? Read why Inhibikase Therapeutics’ Phase 3 launch could become a major 2026 biotech catalyst.
Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical…